इम्यूनोलॉजिकल विकार और इम्यूनोथेरेपी

इम्यूनोलॉजिकल विकार और इम्यूनोथेरेपी
खुला एक्सेस

आईएसएसएन: 2593-8509

अमूर्त

Comparison of Intradermal mesotherapy versus systemic therapy in the treatment of musculoskeletal pain: A prospective randomized study

Abdullah Osman Kocak

Abstract 
Statement of the Problem: Acute musculoskeletal injuries are one of the most common painful presentation whenadmission to the emergency department. The aim of the study is to compare the tenoxicam mesotherapywith intravenous dexketoprofen in pain control in patients with acute musculoskeletal injury.Methods:This parallel randomized controlled trial was conducted with the patients admitted to theemergency department with musculoskeletal injury. Intravenous dexketoprofen was administered tothe control group, and mesotherapy treatment was performed to the other group. Differences between10th, 30th, 60th and 120th minutes VAS scores and on the admission VAS score, clinically meaningfulchange in pain intensity, and adverse effect of the procedures were compared among groups.The results:The differences in VAS scores and the presence of clinically meaningful change in pain inten-sity were statistically significantly higher in mesotherapy group than the systemic therapy group in alltime periods. During one-week follow-up period, there was no reported adverse effect neither inmesotherapy group nor in the systemic therapy group. Conclusion & Significance: The mesotherapy treatment may be superior than the systemic therapy for pain relief inmusculoskeletal injury in short term follow-up in emergency department settings. 

Biography
Abdullah Osman Kocak is a faculty member of the Ataturk University Faculty of Medicine, Department of Emergency Medicine. He is the deputy head of the Emergency Medicine clinic. He completed his university education at the same university. He is a member of the Association of Emergency Medicine Specialists. He has many works in the field.

अस्वीकरण: इस सार का अनुवाद कृत्रिम बुद्धिमत्ता उपकरणों का उपयोग करके किया गया था और अभी तक इसकी समीक्षा या सत्यापन नहीं किया गया है।
Top